Alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Journal of Interventional Cardiology

Volumn 18, Issue 3, 2005, Pages 155-162

  Abbas, Amr E ^a   Brewington, Stacy D ^a   Dixon, Simon R ^a   Grines, Cindy L ^a   O'Neill, William W ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; COLLAGENASE 3; CONTRAST MEDIUM; CREATINE KINASE; CREATINE KINASE MB; GELATINASE A; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALCOHOL SEPTAL ABLATION; COMPLETE HEART BLOCK; CONTRAST ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICULOGRAPHY; HEMODYNAMICS; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MITRAL VALVE REGURGITATION; MORTALITY; MUSCLE RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; THORAX PAIN; TREATMENT INDICATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTI-INFECTIVE AGENTS, LOCAL; CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; HEART CATHETERIZATION; HEART SEPTUM; HUMANS; TREATMENT OUTCOME;

EID: 21744450190     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2005.04107.x     Document Type: Review

References (26)

1. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
2. Singh M, Edwards WD, Holmes DR, et al. Anatomy of the first septal perforating artery: A study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 2001;76:799-802.
3. Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during non surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998;32:225-229.
4. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-670.
5. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgment? (comment). J Am Coll Cardiol 1996;27:431-432.
6. Seggewiss H. Medical therapy versus interventional therapy in hypertrophic obstructive cardiomyopathy. Curr Control Trials Cardiovasc Med 2000;1:115-119.
7. Lakkis NM, Plana JC, Nagueh S, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol 2001;88:583-586.
8. Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: Mechanism of obstruction and response to therapy. Rev Cardiovasc Med 2003;4:199-215.
9. Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000;83:326-331.
10. Nagueh SF, Ommen SR, Lakkis NM, et al. Efficacy of non-surgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. J Am Coll Cardiol 2001;38:1701-1706.
11. Shamim W, Yousufuddin M, Wang D, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326-1333.
12. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-2421.
13. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994-2000.
14. Bradham WS, Gunasinghe H, Holder JR, et al. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2002;40:2165-2173.
15. Runquist LH, Nielsen CD, Killip D, et al. Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2002;90:1020-1022.
16. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients, (comment). Circulation 1997;95:2077-2081.
17. Lakkis NM, Nagueh SF, Dunn JK, et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000;36:852-855.
18. Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003;91:817-821.
19. Abraham TP, Nishimura RA, Holmes DR, Jr, et al. Strain rate imaging for assessment of regional myocardial function: Results from a clinical model of septal ablation. Circulation 2002;105:1403-1406.
20. van Dockum W, ten Cate F, ten Berg J, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.
21. Abbas AE, Brewington SD, Goldstein JA, et al. A novel method for hemodynamic assessment of hypertrophic obstructive cardiomyopathy using cine MRI frame counting. Am J Cardiol 2004;94 (Suppl 1):32E.
22. Brewington SD, Abbas AE, Goldstein JA, et al. Morphological changes in the ventricular septum after alcohol septal ablation: A study using contrast-enhanced magnetic resonance imaging. Am J Cardiol 2004:94 (Suppl 1):119E.
23. Chang SM, Nagueh SF, Spencer III WH, et al. Complete heart block: Determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003;42:296-300.
24. Chang SM, Lakkis NM, Franklin J, et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109(7):824-827.
25. Lakkis NM. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-1755.
26. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342-1354.